Market Research Logo

Global Dermatophytic Onychomycosis Market 2016-2020

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria for dermatophytic onychomycosis drugs
  • Overview: Dermatophytic onychomycosis
    • Types of dermatophytic onychomycosis
    • Risk factors
    • Management
      • Table Percentage of population undergoing treatment globally 2015
      • Table Pharmacological treatment for dermatophytic onychomycosis
      • Table Treatment algorithm for dermatophytic onychomycosis
    • Epidemiology
  • Pipeline analysis
    • TDT 067
    • P-3058
    • MOB-015
    • VT-1161
    • Luliconazole solution, 10%
    • ME1111
    • NP213
    • HXP124
  • Market landscape
    • Market overview
      • Table Global dermatophytic onychomycosis therapeutics market overview
    • Market size and forecast
      • Table Global dermatophytic onychomycosis market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by route of administration
    • Topical
      • Table Comparison of activity of topical medications for onychomycosis
    • Oral
      • Table Comparison of activity of oral medications for onychomycosis
      • Table Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
      • Table Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
  • Geographical segmentation
    • Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
      • Table Segmentation of global dermatophytic onychomycosis market based on geography 2015
      • Table Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
    • Dermatophytic onychomycosis market in Americas
      • Table Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
    • Dermatophytic onychomycosis market in EMEA
      • Table Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
    • Dermatophytic onychomycosis market in APAC
      • Table Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
      • Table Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increase in R&D
    • Growing prevalence of dermatophytic onychomycosis
      • Table Comparison of onychomycosis prevalence with major diseases in US 2013
    • Unmet medical needs
    • Rise in prevalence of diabetes
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Adverse effects and limited efficacy of drugs
    • Lack of awareness
    • Increased availability of generics and alternative therapies
    • Product recalls by US FDA
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increased focus on combination therapies
    • Outsourcing of drugs manufacturing
    • Increase in strategic alliances among vendors
    • Incorporation of novel technology for product development
  • Vendor landscape
    • Competitive scenario
    • Anacor Pharmaceuticals
      • Table Anacor Pharmaceuticals: Key takeaways
    • Galderma
      • Table Galderma: Key takeaways
    • Janssen Biotech
      • Table Janssen Biotech: Key takeaways
    • Novartis
      • Table Novartis: Key takeaways
    • Valeant Pharmaceuticals
      • Table Valeant Pharmaceuticals: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

About Dermatophytic Onychomycosis

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

Technavio’s analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.

The market is divided into the following segments based on geography:

  • APAC
  • EMEA
  • Americas
Technavio's report, Global Dermatophytic Onychomycosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Anacor Pharmaceuticals
  • Galderma
  • Janssen Biotech
  • Novartis
  • Valeant Pharmaceuticals
Other prominent vendors
  • Abeona Therapeutics
  • Allergan
  • Elorac
  • GlaxoSmithKline
  • Hexima
  • Hisamitsu Pharmaceutical
  • Mayne Pharma
  • MediQuest Therapeutics
  • Meiji Seika Pharma
  • Merz Pharma
  • Moberg Pharma
  • NanoBio
  • NovaBiotics
  • Nuvo Research
  • Pfizer
  • Polichem
  • Promius Pharma
  • Sanofi
  • Seren Pharmaceuticals
  • Taro Pharmaceutical
  • Topica Pharmaceuticals
  • Viamet Pharmaceuticals
Market driver
  • Increase in R&D
  • For a full, detailed list, view our report
Market challenge
  • Adverse effects and limited efficacy of drugs
  • For a full, detailed list, view our report
Market trend
  • Increased focus on combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Dermatophytic Onychomycosis Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Dermatophytic Onychomycosis Market: Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis and Valeant Pharmaceuticals

Other Prominent Vendors in the market are: Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals and Viamet Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone. At times, the combination of surgery and systemic and topical therapies are also used. Sometimes, non-pharmacological approaches such as laser or mechanical treatment are also used in combination with topical and systemic therapy. Such trends will have a positive impact on the growth of the market.”

According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.

Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.

Companies Mentioned

Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis, Valeant Pharmaceuticals, Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, Viamet Pharmaceuticals.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;